A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-04-01
DOI
10.1038/srep23899
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity
- (2015) Akihiro Fujimoto et al. Nature Communications
- Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
- (2015) Michele Simbolo et al. Oncotarget
- New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
- (2014) J. S. Ross et al. ONCOLOGIST
- Mutational landscape of intrahepatic cholangiocarcinoma
- (2014) Shanshan Zou et al. Nature Communications
- A Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas
- (2013) Steffen Zender et al. CANCER CELL
- Cell Lineage Tracing Reveals a Biliary Origin of Intrahepatic Cholangiocarcinoma
- (2013) R. V. Guest et al. CANCER RESEARCH
- Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
- (2013) Sumera Rizvi et al. GASTROENTEROLOGY
- PTEN loss and KRAS activation cooperate in murine biliary tract malignancies
- (2013) Victoria Marsh et al. JOURNAL OF PATHOLOGY
- Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
- (2013) Waraporn Chan-on et al. NATURE GENETICS
- Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
- (2013) Yuchen Jiao et al. NATURE GENETICS
- KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma
- (2012) M. R. O'Dell et al. CANCER RESEARCH
- Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
- (2012) Mina Komuta et al. HEPATOLOGY
- Cholangiocarcinomas can originate from hepatocytes in mice
- (2012) Biao Fan et al. JOURNAL OF CLINICAL INVESTIGATION
- Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes
- (2012) Sayaka Sekiya et al. JOURNAL OF CLINICAL INVESTIGATION
- Exome sequencing of liver fluke–associated cholangiocarcinoma
- (2012) Choon Kiat Ong et al. NATURE GENETICS
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
- (2012) Cécile Guichard et al. NATURE GENETICS
- CpG-island methylation study of liver fluke-related cholangiocarcinoma
- (2011) R Sriraksa et al. BRITISH JOURNAL OF CANCER
- The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma
- (2011) Alphonse E. Sirica Nature Reviews Gastroenterology & Hepatology
- High incidence of ras gene mutation in intrahepatic cholangiocarcinoma
- (2010) Minoru Tada et al. CANCER
- The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis
- (2010) K.-P. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3
- (2009) Florin M. Selaru et al. HEPATOLOGY
- Cholangiocarcinoma
- (2008) Boris R.A. Blechacz et al. Clinics in Liver Disease
- A CK19CreERTknockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organs
- (2008) Anna L. Means et al. GENESIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started